Genome-wide DNA copy number predictors of lapatinib sensitivity in tumour-derived cell lines

ABSTRACT: A common aim of pharmacogenomic studies that employ genome-wide assays on panels of cancers is the unbiased discovery of genomic alterations that are associated with clinical outcome and drug response. Previous investigations of lapatinib, a selective dual-kinase inhibitor of EGFR and HER2 tyrosine kinases, have demonstrated predictable relationships between the activity of these genes and response. Under the hypothesis that additional genes may play a role in promoting sensitivity, a predictive model for lapatinib sensitivity was constructed from genome-wide DNA copy number data from 24 cancer cell lines. An optimal predictive model, which consists of aberrations at nine distinct genetic loci, includes gains of HER2, EGFR, and loss of CDKN2A. This model, which achieved area under the Re

ORGANISM(S): Homo sapiens

SUBMITTER: Joel Greshock 

PROVIDER: E-GEOD-9585 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress